Deal strengthen’s Sequenom’s prenatal diagnostic development efforts.
Sequenom gained exclusive rights to patents covering digital PCR technologies and methods through a licensing agreement with Genomic Nanosystems.
The agreement provides Sequenom the use of digital PCR methods on any platform for noninvasive prenatal diagnostics and analysis for any sample, e.g, fetal cells, amniocentesis fluids, plasma, and urine. Sequenom also has the right to use digital PCR methods in conjunction with mass spectrometry for any commercial, diagnostic, or research purpose excluding second generation sequencing.
The deal with Genomic Nanosystems follows closely Sequenom’s license agreement with The Chinese University of Hong Kong. The transaction, which was announced about a week ago, included rights to digital PCR and other noninvasive prenatal diagnostic intellectual property
Digital PCR and Genomic Nanosystems’ portfolio of digital amplification methods provide for detection and quantification of rare and/or foreign genetic sequences for molecular genetic analysis in prenatal diagnostics as well as cancer and infectious disease, according to Luke Ranasinghe, Ph.D., CTO of Genomic Nanosystems.